

# MARKET REPORT



## Cholera - Pipeline Review, H1 2017

**BioPortfolio**  
Life Science Healthcare and  
Pharmaceutical  
Market Research and  
Corporate Data



# Cholera - Pipeline Review, H1 2017

BioPortfolio has been marketing business and market research reports from selected publishers for over fifteen years. BioPortfolio offers a personal service to our customers with dedicated research managers who will work with you to source the best report for your needs. Based in the UK, BioPortfolio is well positioned to coordinate our customers' orders sourced from over 50 global report publishers.

We are pleased to present details of this report to assist your buying decision and administrative process. You will find easy-to-use *How To Buy* information on the last page of this document.

***We look forward to being of service to you.***

*If you have bulk and/or recurring requirements, please get in touch - we can liaise with publishers to obtain sample pages and negotiate discounts on your behalf.*

**Phone:** +44 (0)7887 945155 or **Email:** [bioportfolio97@gmail.com](mailto:bioportfolio97@gmail.com)

# Cholera - Pipeline Review, H1 2017

Cholera - Pipeline Review, H1 2017

## Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Cholera - Pipeline Review, H1 2017, provides an overview of the Cholera (Infectious Disease) pipeline landscape.

Cholera is an acute infectious disease caused by a bacterium, *Vibrio cholera*, which results in a painless, watery diarrhea in humans. Symptoms of cholera can begin as soon as a few hours or as long as five days after infection. Often symptoms are mild. But sometimes they are very serious. Signs and symptoms of Cholera include rapid heart rate, loss of skin elasticity, low blood pressure, thirst, muscle cramps. If not treated, this can lead to shock and death in a matter of hours.

## Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Cholera - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Cholera (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Cholera (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Cholera and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I and Preclinical stages are 2, 1 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 1, 1, 5 and 2 molecules, respectively.

Cholera (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

## Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Cholera (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Cholera (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Cholera (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Cholera (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Cholera (Infectious Disease)

#### Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Cholera (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Cholera (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

## Additional Details

**Publisher** : Global Markets Direct

**Reference** : GMDHC8989IDB

**Number of Pages** : 42

**Report Format** : PDF

**Publisher Information** :

**Global Markets Direct**  
The home of leading edge research and analysis

**BioPortfolio**  
Life Science Healthcare and Pharmaceutical  
Global Market Research and Corporate Data

**BioPortfolio**  
Life Science Healthcare and Pharmaceutical  
Market Research and  
Corporate Data

**Best Prices  
Guaranteed**

**bioportfolio.co.uk**

# Table Of Contents for Cholera - Pipeline Review, H1 2017

- Table of ContentsList of TablesList of FiguresIntroductionGlobal Markets Direct Report CoverageCholera - OverviewCholera - Therapeutics DevelopmentPipeline OverviewPipeline by CompaniesPipeline by Universities/InstitutesProducts under Development by CompaniesProducts under Development by Universities/InstitutesCholera - Therapeutics AssessmentAssessment by TargetAssessment by Mechanism of ActionAssessment by Route of AdministrationAssessment by Molecule TypeCholera - Companies Involved in Therapeutics DevelopmentAkhelia Pharmaceuticals LtdBeijing Minhai Biotechnology Co LtdMSD Wellcome Trust Hilleman Laboratories Pvt LtdNapo Pharmaceuticals IncCholera - Drug ProfilesAKT-10082 - Drug ProfileProduct DescriptionMechanism Of ActionR&D Progresscholera (trivalent) vaccine - Drug ProfileProduct DescriptionMechanism Of ActionR&D Progresscholera (whole cell) vaccine - Drug ProfileProduct DescriptionMechanism Of ActionR&D Progresscholera [strain O1/EI/Tor/Ogawa] vaccine - Drug ProfileProduct DescriptionMechanism Of ActionR&D Progresscholera vaccine - Drug ProfileProduct DescriptionMechanism Of ActionR&D Progresscholvax - Drug ProfileProduct DescriptionMechanism Of ActionR&D Progresscrofelemer DR - Drug ProfileProduct DescriptionMechanism Of ActionR&D Progressgram-negative bacterial infections vaccine - Drug ProfileProduct DescriptionMechanism Of ActionR&D ProgressIMSUTMR-1501 - Drug ProfileProduct DescriptionMechanism Of ActionR&D ProgressPeptide for Cholera and Guillain-Barre Syndrome - Drug ProfileProduct DescriptionMechanism Of ActionR&D ProgressSmall Molecules for Bacterial Infections - Drug ProfileProduct DescriptionMechanism Of ActionR&D ProgressSmall Molecules to Inhibit Sialic Acid Permease for Gram Negative Bacterial Infections - Drug ProfileProduct DescriptionMechanism Of ActionR&D ProgressSynthetic Peptides to Disrupt Cell Membrane for Bacterial and Fungal Infections - Drug ProfileProduct DescriptionMechanism Of ActionR&D ProgressCholera - Dormant ProjectsCholera - Discontinued ProductsCholera - Product Development MilestonesFeatured News & Press ReleasesApr 27, 2016: Hilleman Laboratories Provides Phase I/II Update on Cholera VaccineFeb 03, 2015: Napo Files Brief on Appeal In Dispute With SalixAppendixMethodologyCoverageSecondary ResearchPrimary ResearchExpert Panel ValidationContact UsDisclaimer



# How to Buy...

Cholera - Pipeline Review, H1 2017

## Option 1 - Online

Go to our website and pay online with any major debit or credit card:

<https://www.bioportfolio.co.uk/product/47388>

## Option 2 - Request a Proforma Invoice

Fill in the details below, and **Scan** this page **and email** it to us at [bioportfolio97@gmail.com](mailto:bioportfolio97@gmail.com) We will send you a Proforma Invoice and deliver your report on settlement.

**Your Name:** .....

**Job Title:** .....

**Your Email:** .....

**Your Contact Phone:** .....

**Company Name:** .....

**Address:** .....

**Post/Zip Code:** .....

**Country:** .....

**P.O. Number:** .....

**Any Other Instructions:** .....

**Pricing Options:** (please tick one)

- \$1700** | Single User Price
- \$3400** | Site License Price
- \$5100** | Enterprise License Price

**Payment Options:** (please tick one)

- Online Credit Card** (we will email you the invoice with a payment link)
- Direct Wire Transfer** (we will email you the invoice with our bank details)

**Authorising Signature:** .....

## Option 3 - Phone Us on +44 (0)7887 945155

We will be delighted to give you our personal attention.